. If ATP hydrolysis by p68 is required for displacement of β-catenin from Axin as suggested but yet to be demonstrated by Yang et al. (2006b) , is it possible that the Axin complex contains an RNA that activates p68 ATPase? Or is p68 a protein-dependent (more specifically, β-catenin-dependent) ATPase as well? Tyrosine 593 of p68 is conserved in vertebrates (but not in invertebrates) and is located in the p68 carboxyl terminus outside the globular catalytic core (Rocak and Linder 2004) . Does phosphorylation at this site regulate p68 catalytic function in addition to providing an interaction interface for β-catenin? Finally, as EMT has been implicated in cancer invasion (Thiery and Sleeman 2006) , inhibitors of the c-Abl-p68-β-catenin pathway may be beneficial in preventing metastasis of tumor cells. In this regard, it is worth considering whether STI571/Gleevac-which inhibits c-Abl (and PDGF) signaling and is a potent anti-cancer drug for certain blood and solid tumors-may act in part by inhibiting the p68-β-catenin pathway and whether Gleevec may exhibit efficacy in preventing metastasis of other cancer types.
Studies in many different areas of cancer research including epidemiological studies have established the connection between inflammation and cancer (Balkwill et al., 2005; Balkwill and Mantovani, 2001; Coussens and Werb, 2002) . For example, inflammatory bowel disease is a risk factor for the development of colorectal cancer. Moreover, the usage of nonsteroid anti-inflammatory agents is associated with protection against various tumors, and these drugs have been investigated as possible anticancer agents. Even tumors where a firm connection to inflammation has not been established, such as breast cancer, exhibit an inflammatory microenvironment at the site of the tumor. Indeed, an inflammatory component is present in the microenvironment of most neoplastic tissues. In this context, Chien et al. (2006) now identify a signaling pathway mediated by the RalB GTPase that regulates both tumor survival and the inflammatory response.
Many of the inflammatory factors that promote tumorigenesis are generated by cells in the tumor microenviroment, and not by the cancer cells themselves (called the "extrinsic" pathway in Figure 1 ) (Balkwill et al., 2005; Balkwill and Mantovani, 2001; Coussens and Werb, 2002 A connection between the genetic events that lead to tumor formation and the signaling pathways of the innate immune response has been established. In this issue, Chien et al. (2006) show that the RalB GTPase regulates the IKK family member TBK1, providing an unexpected link between the signaling pathways that promote inflammation and cancer. In tumor cells the RalB/TBK1 pathway inhibits apoptosis and in nontumorigenic cells it stimulates an innate immune response.
Cell 127, October 6, 2006 ©2006 Elsevier Inc. 43 blood cells including tumor-associated macrophages (TAM), mast cells, eosinophils, and polymorphonuclear leukocytes (PMN). These cells create an inflammatory microenvironment by secreting cytokines and chemokines that contribute to tissue remodeling and angiogenesis (Balkwill et al., 2005; Balkwill and Mantovani, 2001 ). The molecular pathways of inflammation leading to tumor promotion have been dissected in mutant mice. Such studies have revealed the role of particular elements of the inflammatory process in different steps of tumor progression in diverse tissues (such as skin, liver, mammary gland, and intestine). The factors identified so far include tumor necrosis factor, interleukin-1, the macrophage growth and attractant factor CSF-1, the prostaglandin-producing enzyme cyclooxygenase 2, the master inflammatory transcription factor NF-κB, and enzymes involved in tissue remodeling (Balkwill et al. 2005 ; Coussens and Werb, 2002; Karin, 2006) .
Additionally, a number of reports, including the study by Chien et al. (2006) , indicate that there are also pathways intrinsic to cancer cells (Figure 1 ) that contribute to inflammation and tumorigenesis. Chien et al. (2006) studied signaling by the RalB GTPase, a member of the Ras GTPase superfamily, which blocks apoptosis in tumor cell lines. In the new work, these authors sought to determine which of the RalB effectors promotes cell survival in human epithelial tumor cells. Among the many RalB effectors tested, Chien et al. found that Sec5 is needed to mediate the prosurvival function of RalB in cancer cells. Although Sec5 is best known for its involvement in the trafficking of secretory vesicles as part of the exocyst complex, its role in cell survival may be separate from this function.
Surprisingly, subsequent purification of the exocyst complex revealed the presence of TBK1/NAK (Tank binding kinase 1/NF-κB activating kinase), a core component of the innate immune response that acts downstream of Toll-like receptors (TLRs). Chien et al. next provided evidence that RalB activates TBK1 by promoting the association of TBK1 with Sec5. They showed that mouse embryonic fibroblasts that lack TBK1 were resistant to transformation stimulated by oncogenic Kras. In contrast, if kinase-dead TBK1 is expressed in mouse embryonic fibroblasts also expressing oncogenic K-ras, the cells undergo apoptosis. Thus, the authors conclude that RalB/ TBK1 controls a cell-autonomous host defense signaling pathway that inhibits tumor cell apoptosis. In contrast to cancer cell lines, Chien et al. find that the RalB/Sec5/TBK1 pathway does not affect the survival of nontumorigenic epithelial cells.
In the innate immune pathway, TBK1 activates the transcription factors p65Rel and interferon regulatory factor 3 (IRF-3), which translocate to the nucleus and promote the expression of cytokines including interferon β. Chien et al. provide evidence that RalB helps trigger this response in nontumorigenic human epithelial cells following stimulation with dsRNA or Sendai virus, which activate TLRs. Thus, Chien et al. make two surprising and interlinked discoveries-that the RelB/TBK1 pathway has critical roles both in tumor cell survival and in innate immunity.
Other pathways intrinsic to cancer cells that are involved in neoplastic transformation result in activation of innate immunity and inflammation. Expression of activated Ras in HeLa cells (a cervical carcinoma cell line) induces production of the chemokine CXCL8, also known as IL-8, which promotes angiogenesis and tumor progression. In addition, the chemokine receptor CXCR4, which is implicated in cell survival and metastasis, is frequently expressed on the surface of malignant cells. The expression of CXCR4 is upregulated by mutations in von Hippel Lindau factor, as is the expression of the inflammatory cytokine TNF-α (reviewed in Balkwill et al., 2005) . Mutation of the tumor suppressor gene PTEN in non-small cell lung cancer also results in upregu- lation of the activity of HIF-1 and in HIF-1-dependent transcription of the CXCR4 gene (Phillips et al., 2005) . Another example of an intrinsic pathway is provided by gene rearrangements involving a tyrosine kinase (Ret-PTC) that results in papillary thyroid carcinoma. This gene rearrangement activates an inflammatory program that includes production of inflammatory chemokines and expression of CXCR4 in primary human thyroid cells (Borrello et al., 2005) . Also, the oncogene BRAF, which is frequently activated in malignant melanoma, induces cytokine production contributing to a tumor-promoting milieu (Sumimoto et al., 2006) . Another important factor is α-catenin. Its ablation results in NF-κB activation, induction of genes involved in inflammation, cell proliferation, and ultimately squamous cell carcinoma (Kobielak and Fuchs, 2006) . Although Chien et al. report elevated TBK1 activity in some established human carcinoma lines, the relevance of the RalB pathway to human neoplasia remains to be established. However, it is interesting that human malignant plasmacytomas (B cell tumors) have been shown to overexpress members of the TLR family that activate the TBK/ IRF pathway (Bohnhorst et al., 2006) .
Chien et al. emphasize the importance of the RalB/TBK1 pathway for cell-autonomous survival, although we surmise that the same innate immunity pathway might activate the production of inflammatory mediators contributing to a tumor-promoting inflammatory microenvironment (the extrinsic pathway in Figure 1 ). This may help to explain why many cell lines derived from advanced malignancies generate an autocrine cytokine network. Regardless of whether or not TBK1 acts intrinsically in cancer cells to promote cell survival or contributes to a proinflammatory environment, the work of Chien et al. (2006) suggests that targeting TBK1 may be therapeutically beneficial for the treatment of certain tumors.
